Mrugala, M. M., Shi, W., Iwomoto, F., Lukas, R. V., Palmer, J. D., Suh, J. H., & Glas, M. (2024). Global post‑marketing safety surveillance of Tumor Treating Fields (TTFields) therapy in over 25,000 patients with CNS malignancies treated between 2011–2022. Journal of Neuro-Oncology, 169(1), 25–38. https://doi.org/10.1007/s11060-024-04682-7

Cao, Q., Hajosch, A., Kast, R. E., Loehmann, C., Hlavac, M., Fischer-Posovszky, P., Strobel, H., Westhoff, M.-A., Siegelin, M. D., Wirtz, C. R., Halatsch, M.-E., & Karpel-Massler, G. (2024). Tumor Treating Fields (TTFields) combined with the drug repurposing approach CUSP9v3 induce metabolic reprogramming and synergistic anti-glioblastoma activity in vitro. British Journal of Cancer, 130(8), 1365–1376. https://doi.org/10.1038/s41416-024-02608-8

Wang, C. N., & Chung, D. E. (2022). Neuromodulation for lower urinary tract symptoms in special populations. Neurourology and Urodynamics, 41(8), 1948–1957. Portico. https://doi.org/10.1002/nau.24954

Fogel, H. P., & Winfree, C. J. (2022). What’s New in Peripheral Nerve Stimulation. Neurosurgery Clinics of North America, 33(3), 323–330. https://doi.org/10.1016/j.nec.2022.02.009